Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind outpatient COVID-19 trial of S-217622 vs placebo
2021-006504-32Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing S-217622 with Placebo (2 arms). Primary endpoint: Primary clinical endpoint. Started Sep 2022; status: completed.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006504-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006504-32.